Publication Name	World Journal of Clinical Oncology
Manuscript ID	93717
Country	Portugal

Received	2024-03-04 19:28
Peer-Review Started	2024-03-04 19:29
To Make the First Decision
Return for Revision	2024-07-09 21:02
Revised	2024-07-22 18:18
Second Decision	2024-08-15 04:50
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-08-15 09:45
Articles in Press	2024-08-15 09:45
Publication Fee Transferred	2024-08-17 23:00
Edit the Manuscript by Language Editor	2024-08-20 17:43
Typeset the Manuscript	2024-08-22 00:30
Publish the Manuscript Online	2024-08-29 08:28

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Case Report
Article Title	Successful cetuximab rechallenge in metastatic colorectal cancer: A case report
Manuscript Source	Unsolicited Manuscript
All Author List	Alexandra Guedes, Sandra Silva, Sandra Custódio and Andreia Capela
Funding Agency and Grant Number
Corresponding Author	Alexandra Guedes, MD, Doctor, Doctor, Department of Medical Oncology, Centro Hospitalar Gaia/Espinho, Rua Conceição Fernandes S/N, Vila Nova de Gaia 4434-502, Portugal. alexandra.pereira.guedes@ulsge.min-saude.pt
Key Words	Metastatic colorectal cancer; RAS mutation; RAS wild type; Anti-epidermal growth factor receptor; Cetuximab; Rechallenge; Case report
Core Tip	In RAS-wild type patients treated with anti-epidermal growth factor receptor-inhibitors, the emergence of RAS mutations leads to resistance to further anti-epidermal growth factor receptor treatment. However, resistant clones seem to decay over time upon treatment withdrawal. Liquid biopsy-driven cetuximab rechallenge can be effective in later lines of treatment of metastatic colorectal cancer. Longer anti-epidermal growth factor receptor-free intervals may act as a surrogate for improved responses and survival outcomes.
Publish Date	2024-08-29 08:28
Citation	<p>Guedes A, Silva S, Custódio S, Capela A. Successful cetuximab rechallenge in metastatic colorectal cancer: A case report. <i>World J Clin Oncol</i> 2024; 15(9): 1232-1238</p>
URL	https://www.wjgnet.com/2218-4333/full/v15/i9/1232.htm
DOI	https://dx.doi.org/10.5306/wjco.v15.i9.1232

Full Article (PDF)	WJCO-15-1232-with-cover.pdf
CARE Checklist–2016	93717-CARE-Checklist-2016.pdf
Manuscript File	93717_Auto_Edited_082538.docx
Answering Reviewers	93717-answering-reviewers.pdf
Audio Core Tip	93717-audio.m4a
Conflict-of-Interest Disclosure Form	93717-conflict-of-interest-statement.pdf
Copyright License Agreement	93717-copyright-assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	93717-foundation-statement.pdf
Signed Consent for Treatment Form(s) or Document(s)	93717-informed-consent-statement.pdf
Non-Native Speakers of English Editing Certificate	93717-non-native-speakers.pdf
Peer-review Report	93717-peer-reviews.pdf
Scientific Misconduct Check	93717-scientific-misconduct-check.png
Scientific Editor Work List	93717-scientific-editor-work-list.pdf
CrossCheck Report	93717-crosscheck-report.pdf